A.Giaccari1 · G. Gliozzo1 · G. Ciccarelli1 · G. Di Giuseppe1 · C. Castellano2 · S. Cum3 · L. Delle Monache4,13 · M. Gallo5 ·M.Lastretti6 · G. Medea7 · M. Monesi8 · R. Napoli9 · B. Pintaudi10 · E. Succurro11 · G. Turchetti
Received: 9 January 2026 / Accepted: 17 March 2026 © The Author(s) 2026
Abstract
Background and aims Although continuous glucose monitoring (CGM) devices are now standard of care among Type 1 diabetes patients, they are still relatively underutilized in Type 2 diabetes (T2D), particularly in those patients not treated with insulin. Widespread adoption continues to be hindered by a combination of factors. Chief among these is the scarcity of long-term, large-scale clinical trials demonstrating the benefits of the use of CGM in T2D. This meta-analysis aimed to address this gap by comparing CGM with self-blood glucose monitoring (SBMG), with primary outcomes of HbA1c and time in range (TIR) in insulin-treated and non-insulin-treated TD2 patients.
Methods and results Following the stringent rules mandated by our National Health Service (which requires a panel com-posed of all stakeholders involved in diabetes treatment, and includes PICO, GRADE, AGREE, and meta-analyses), we performed a systematic review of RCTs that enrolled two groups of individuals with T2D, those treated with insulin (includ-ing basal and basal-bolus regimens), and those receiving treatments other than insulin. All included trials compared CGM with structured blood glucose monitoring (SBGM) with glycated hemoglobin (HbA1c) as the main endpoint. Based on the strength and consistency of the evidence, the panel issued a strong recommendation in favor of CGM for individuals with T2D treated with insulin (including those on basal insulin alone) and for individuals with T2D not treated with insulin, par-ticularly for those with glycated hemoglobin levels≥7%. From a pharmacoeconomic perspective, outcomes were positive in both patient groups.
Conclusion CGM represents a clinically effective and cost-efficient approach to optimizing glycemic control in T2D, becom-ing mandatory among individuals on insulin therapy. Our findings support a shift in clinical practice toward the more widespread use of CGM in T2D, with regulatory frameworks and reimbursement policies needing to adapt accordingly.
Keywords CGM · Type 2 Diabetes · Metanalysis · PICO · GRADE · Guidelines
Communicated by Massimo Federici, M.D.
A. Giaccari 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
1 Center for Endocrine and Metabolic Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS and Università Cattolica del Sacro Cuore, Rome, Italy
2 Azienda USL of Modena, Sassuolo Hospital, Sassuolo, Italy
3 Diabetes and Diabetic Foot Care Unit, ASUGI, Monfalcone, Italy
4 National Board Member of FAND (Italian Association for the Rights of Diabetic People), Roma, Italy
5 Department of Endocrinology and Metabolic Diseases, AO SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
6 Order of Psychologists of Lazio, Rome, Italy
7 Italian Society of General Medicine (SIMG), Florence, Italy
8 Territorial Diabetology Unit, AUSL Ferrara, Ferrara, Italy
9 Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy
10 Diabetes Unit, Niguarda Cà Granda Hospital, Milan, Italy
11 Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy
12 Institute of Management, Scuola Superiore Sant’Anna, Pisa, Italy
13 Patient Advocacy Lab, ALTEMS – Università Cattolica del Sacro Cuore, Rome, Italy
版权归中华医学会所有。
未经授权,不得转载、摘编本刊文章。
引用本文:简喜超, 简扬, 邓呈亮. 2025版《中国糖尿病足防治实践指南》解读[J]. 中华医学美学美容杂志, 2026, 32(2): 99-103. DOI: 10.3760/cma.j.cn114657-20251215-00266.
通信作者:邓呈亮,Email:该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
Xianghua Zhang1 Delphine Kerob2 Zhongxing Zhang1 Han Tao1 Xiaofeng He3 Yi Yi3 Xiaofeng Fang3 Wenna Wang3 Andrew Steel3
1 L’Oreal Dermatological Beauty, L’Oréal China, Shanghai, China
2 La Roche-Posay Laboratoire Pharmaceutique, Levallois Perret, La Roche-Posay, France
3 Research and Innovation Center, L’Oréal China, Shanghai, China
Correspondence
Xianghua Zhang, L’Oreal Dermatological Beauty, L’Oréal China, Shanghai, China.
Email: 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
Background: Sensitive skin is a common condition affecting a significant proportion of the population, and there is a growing demand for effective and safe management.
Aim: To evaluate the efficacy and safety of a cream containing panthenol, prebiotics, and probiotic lysate as an optimal care for facial sensitive skin.
Methods: A total of 110 participants (64 in group A and 46 in group B) with facial sensitive skin applied the cream twice daily for 28 days. Group A evaluated their sensitive skin, product efficacy, and product use experience at D0 (15 min), D1, D14, and D28. In group B, skin barrier function-related indicators were measured at baseline and on D1, D7, D14, and D28. Dermatologists evaluated tolerance for all participants.
Results: After 28 days of use, in group A, 100% of participants reported mildness and comfort with product use. Participants demonstrated significant improvements in skin barrier function-related indicators, including increased stratum corneum moisture content, reduced erythema index, elevated sebum content, decreased trans-epidermal water loss, and diminished skin redness parameter a* value (all p < 0.05). Dermatologist evaluations revealed excellent tolerance among all participants.
Conclusion: The panthenol-enriched cream with prebiotics and probiotic lysate exhibited substantial clinical efficacy in ameliorating facial sensitive skin conditions, coupled with a high safety profile.
KEYWORDS panthenol, prebiotics, probiotics, sensitive skin, skin barrier function
Marta Arnal‑Forné1 · Tamara Molina‑García2 · María Ortega2 · Víctor Marcos‑Garcés2,3 · Pilar Molina4 · Antonio Ferrández‑Izquierdo1,2,5 · Pilar Sepulveda1,6,7 · Vicente Bodí2,3,6,8 · César Ríos‑Navarro1,2,6 · Amparo Ruiz‑Saurí1,2,6
Accepted: 10 June 2024 / Published online: 2 July 2024
© The Author(s) 2024
Skin represents the main barrier against the external environment, but also plays a role in human relations, as one of the prime determinants of beauty, resulting in a high consumer demand for skincare-related pharmaceutical products. Given the importance of skin aging in both medical and social spheres, the present research aims to characterize microscopic changes in human skin composition due to intrinsic aging (as opposed to aging infuenced by external factors) via histological analysis of a photoprotected body region. Samples from 25 autopsies were taken from the periumbilical area and classifed into four age groups: group 1 (0–12 years), group 2 (13–25 years), group 3 (26–54 years), and group 4 (≥55 years). Diferent traditional histological (hematoxylin–eosin, Masson’s trichrome, orcein, toluidine, Alcian blue, and Feulgen reaction) and immunohistochemical (CK20, CD1a, Ki67, and CD31) stains were performed. A total of 1879 images photographed with a Leica DM3000 optical microscope were morphometrically analyzed using Image ProPlus 7.0 for further statistical analysis with GraphPad 9.0. Our results showed a reduction in epidermis thickness, interdigitation and mitotic indexes, while melanocyte count was raised. Papillary but not reticular dermis showed increased thickness with aging. Specifcally, in the papillary layer mast cells and glycosaminoglycans were expanded, whereas the reticular dermis displayed a diminution in glycosaminoglycans and elastic fbers. Moreover, total cellularity and vascularization of both dermises were diminished with aging. This morphometric analysis of photoprotected areas reveals that intrinsic aging signifcantly infuences human skin composition. This study paves the way for further research into the molecular basis underpinning these alterations, and into potential antiaging strategies.
Keywords Skin aging · Intrinsic aging · Morphometric analysis · Human biopsies
César Ríos-Navarro
该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
* Amparo Ruiz-Saurí 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。; 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
1 Department of Pathology, University of Valencia, Avda. Blasco Ibáñez 15. 46010, Valencia, Spain
2 Instituto de Investigación Sanitaria INCLIVA Biomedical Research Institute, Avda. Menéndez Pelayo 4acc,
46010 Valencia, Spain
3 Cardiology Department, Hospital Clínico Universitario, Valencia, Spain
4 Department of Pathology, Instituto de Medicina Legal y Ciencias Forenses, Valencia, Spain
5 Anatomic Pathology Department, Hospital Clínico Universitario, Valencia, Spain
6 Centro de Investigación Biomédica en Red (CIBER)-CV, Madrid, Spain
7 Regenerative Medicine and Heart Transplantation Unit, Instituto de Investigación Sanitaria La Fe, Valencia, Spain
8 Department of Medicine, University of Valencia, Valencia, Spain
Nguyen Ngan Giang1,2 Hyun Ji Kim3 Pham Ngoc Chien2,3 Han Jin Kwon4 Jung Ryul Ham4 Won Ku Lee4 Yeon Ju Gu4 Shou Yi Zhou2,5 Xin Rui Zhang2,5 Sun Young Nam2 Chan Yeong Heo1,2,3,5
1 Department of Medical Device Development, College of Medicine, Seoul National University, Seoul, Republic of Korea
2 Department of Plastic and Reconstructive Surgery, Seoul National University Bundang Hospital, Seongnam, South Korea
3 Korea Institute of Nonclinical Study, H&Bio. co. Ltd., Seongnam, Republic of Korea
4 UltraV Co., Ltd. R&D Center, Seoul, South Korea
5 Department of Medicine, College of Medicine, Seoul National University, Seoul, Republic of Korea
Correspondence Sun Young Nam and Chan Yeong Heo, Department of Plastic and Reconstructive Surgery, Seoul National University Bundang Hospital, Seongnam, Korea.
Email: 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。 and 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
Background: Injectable filler, a nonsurgical beauty method, has gained popularity in rejuvenating sagging skin. In this study, polydioxanone (PDO) was utilized as the main component of the ULTRACOL200 filler that helps stimulate collagenesis and provide skin radiant effects. The study aimed to evaluate and compare the effectiveness of ULTRACOL200 with other commercialized products in visually improving dermatological problems.
Methods: Herein, 31 participants aged between 20 and 59 years were enrolled in the study. 1 mL of the testing product, as well as the quantity for the compared groups was injected into each participants face side individually. Subsequently, skin texture and sunken volume of skin were measured using ANTERA 3D CS imaging technology at three periods: before the application, 4 weeks after the initial application, and 4 weeks after the 2nd application of ULTRACOL200.
Results: The final results of skin texture and wrinkle volume evaluation consistently demonstrated significant enhancement. Consequently, subjective questionnaires were provided to the participants to evaluate the efficacy of the testing product, illustrating satisfactory responses after the twice applications.
Conclusion: The investigation has contributed substantially to the comprehension of a PDO-based filler (ULTRACOL200) for skin enhancement and provided profound insight for future clinical trials.
KEYWORDS collagen formation, filler, polydioxanone, skin enhancement, Ultracol200
黄韶斌 1 胡志成 1 张逸 2 唐冰 1 王鹏 1 徐海琳 1 王志勇 1 董云先 1 程璞 1 荣燕超 1 吴军 3 朱家源 1
1 中山大学附属第一医院烧伤科,广州 510080;
2 南通大学附属医院烧伤整形外科 226001;3 深圳大学第一附属医院烧伤整形科 518037 通信作者:朱家源,Email:该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
伤口世界平台生态圈,以“关爱人间所有伤口患者”为愿景,连接、整合和拓展线上和线下的管理慢性伤口的资源,倡导远程、就近和居家管理慢性伤口,解决伤口专家的碎片化时间的价值创造、诊疗经验的裂变复制、和患者的就近、居家和低成本管理慢性伤口的问题。
2019广东省医疗行业协会伤口管理分会年会
扫一扫了解详情:
任何关于疾病的建议都不能替代执业医师的面对面诊断。所有门诊时间仅供参考,最终以医院当日公布为准。
网友、医生言论仅代表其个人观点,不代表本站同意其说法,请谨慎参阅,本站不承担由此引起的法律责任。